妊娠期抗癫痫药物清除率变化及其对癫痫女性的临床意义
该前瞻性研究纳入妊娠前或妊娠早期入组的癫痫女性,随访至产后第一年,发现左乙拉西坦清除率在妊娠早期达峰值(基线1.71倍),奥卡西平与托吡酯在妊娠中期达峰值(分别为1.63倍与1.39倍),且单药治疗者中清除率比值降低与癫痫发作频率增加相关。
要点
- 左乙拉西坦清除率在妊娠早期达峰值,为基线1.71倍(p=0.0001)。
- 奥卡西平与托吡酯清除率在妊娠中期达峰值,分别为1.63倍(p=0.0001)与1.39倍(p=0.025)。
- 单药治疗者中,与目标浓度比值降低与癫痫发作频率增加相关(p<0.05)。
核心结论
- 左乙拉西坦清除率在妊娠早期即显著变化,奥卡西平与托吡酯在妊娠中期显著变化。
- 较低的与目标浓度比值与癫痫发作恶化相关。
- 早期治疗药物监测和剂量调整可能有助于避免癫痫发作频率增加。
研究设计与样本
- 前瞻性研究,纳入妊娠前或妊娠早期入组的癫痫女性,随访整个妊娠期及产后第一年。
- 通过每日日记记录抗癫痫药物剂量、依从性和癫痫发作,每1-3个月进行药物浓度测量。
- 采用混合线性回归模型比较各孕期清除率与非妊娠基线,调整年龄、种族和给药后时间。
- 单药治疗者中,采用两样本t检验比较各孕期癫痫恶化者与无恶化者的与目标浓度比值。
主要发现
- 左乙拉西坦(n=18次妊娠)平均最大清除率在妊娠早期达基线1.71倍(p=0.0001)。
- 奥卡西平(n=4次妊娠)平均最大清除率在妊娠中期达基线1.63倍(p=0.0001)。
- 托吡酯(n=10次妊娠)平均最大清除率在妊娠中期达基线1.39倍(p=0.025)。
- 丙戊酸(n=5次妊娠)和苯妥英(n=7次妊娠)的清除率数据已计算但未报告最大清除率数值。
- 15例单药治疗女性中,妊娠早期、中期及所有孕期癫痫发作频率增加与较低的与目标浓度比值相关(p<0.05)。
临床怎么用
- 作者认为,早期治疗药物监测和剂量调整可能有助于避免癫痫发作频率增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the magnitude and time course of pregnancy-related clearance changes for different antiepileptic drugs (AEDs): levetiracetam, oxcarbazepine, topiramate, phenytoin, and valproate. A secondary aim was to determine if a decreased AED serum concentration was associated with increased seizure frequency. METHODS: Women with epilepsy were enrolled preconception or early in pregnancy and prospectively followed throughout pregnancy and the first postpartum year with daily diaries of AED doses, adherence, and seizures. Study visits with AED concentration measurements occurred every 1-3 months. AED clearances in each trimester were compared to nonpregnant baseline using a mixed linear regression model, with adjustments for age, race, and hours postdose. In women on monotherapy, 2-sample t test was used to compare the ratio to target concentrations (RTC) between women with seizure worsening each trimester and those without. RESULTS: AED clearances were calculated for levetiracetam (n = 18 pregnancies), oxcarbazepine (n = 4), topiramate (n = 10), valproate (n = 5), and phenytoin (n = 7). Mean maximal clearances were reached for (1) levetiracetam in first trimester (1.71-fold baseline clearance) (p = 0.0001), (2) oxcarbazepine in second trimester (1.63-fold) (p = 0.0001), and (3) topiramate in second trimester (1.39-fold) (p = 0.025). In 15 women on AED monotherapy, increased seizure frequency in the first, second, and all trimesters was associated with a lower RTC (p < 0.05). CONCLUSION: AED clearance significantly changes by the first trimester for levetiracetam and by the second trimester for oxcarbazepine and topiramate. Lower RTC was associated with seizure worsening. Early therapeutic drug monitoring and dose adjustment may be helpful to avoid increased seizure frequency.
引用
- Voinescu PE, Park S, Chen LQ, et al. Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy. Neurology. 2018. PMID: 30185446. doi:10.1212/WNL.0000000000006240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。